Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 31 | SFEBES2013 | Next issue

Society for Endocrinology BES 2013

ea0031cmw2.1 | How Do I Do It? | SFEBES2013

Abstract unavailable....

ea0031cmw2.2 | How Do I Do It? | SFEBES2013

How do I investigate and manage hypomagnesaemia?

Ayuk John

Serum magnesium concentration is regulated by the balance between intestinal absorption and renal excretion. Hypomagnesaemia is relatively common, with an estimated prevalence in the general population ranging from 2.5 to 15%. It may result from inadequate magnesium intake, increased gastrointestinal or renal loss, or redistribution from extracellular to intracellular space. Drug-induced hypomagnesaemia, particularly related to proton-pump inhibitor (PPI) therapy, is being inc...

ea0031cmw2.3 | How Do I Do It? | SFEBES2013

How do I monitor and follow up transgender patients using hormonal therapies?

Seal Leighton

Gender identity disorder is not a rare condition occurring in 1:7440 born male and 1:31 153 born female individuals. Although gender transition is supervised in specialist clinics, post transition the patients are discharged back to primary or secondary care follow up. In my session I will discuss the process of gender transition, common hormonal regimens used and their monitoring. I will also discuss safety studies and the monitoring of long term follow up of individuals taki...

ea0031cmw2.4 | How Do I Do It? | SFEBES2013

How do I manage the pregnant patient with a prolactinoma?

Bevan John S

There are two issues: i) dopamine agonist (DA) safety for mother and baby, and ii) risk of oestrogen-induced prolactinoma enlargement. Bromocriptine (BC) and Cabergoline (CAB) are both safe for ovulation induction but the safety database is larger for BC (6239 pregnancies) than for CAB (789). Neither drug causes increases in miscarriage, premature delivery, multiple births or congenital malformations, compared to data for normal pregnancy. Risk of symptomatic tumour enlargemen...

ea0031cmw2.5 | How Do I Do It? | SFEBES2013

How and when do I induce puberty in males?

Banerjee Indi

Induction of puberty may be required in boys, if puberty is either delayed or arrested. Boys with delayed puberty are often significantly concerned about their physical immaturity, short stature and perceived difference in appearance from peers. The commonest cause of delayed puberty is constitutional delay of growth and puberty (CDGP), a relatively benign condition. However, hypergonadotrophic hypogonadism due to Klinefelter syndrome and hypogonadotrophic hypogonadism (HH) du...

ea0031cmw2.6 | How Do I Do It? | SFEBES2013

Abstract unavailable....